WUXI BIOLOGICS (CAYMAN) INC.
藥明生物技術有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2269)

INSIDE INFORMATION
2026 INTERIM RESULTS PRESENTATION

This announcement is made by WuXi Biologics (Cayman) Inc. (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

In order to enable shareholders and potential investors of the Company to have a deeper and more comprehensive understanding of its 2026 interim results and business operations, the Company will convene conference calls at 9:00 a.m. and 8:00 p.m. (Hong Kong time) on August 26, 2026, at which it will conduct a presentation regarding the Company's financial results and business operations (the "**Presentation**"). Shareholders and potential investors of the Company may attend the conference calls at the scheduled time at the following links:

Conference call in Chinese at 9:00 a.m. (Hong Kong time):

https://s.comein.cn/xyzwy1qm

Conference call in English at 8:00 p.m. (Hong Kong time):

https://jpmchase.zoom.us/webinar/register/WN_MdKQ2PoTRvitg4v65i4wlw#/registration

Please use the links provided above to complete the online registration process in advance of the conference calls.

Further, to ensure that all shareholders and potential investors of the Company have equal and timely access to such information, the Company has included in this announcement the full copy of the Presentation. Shareholders and potential investors of the Company are reminded that the Presentation may contain forward-looking statements, which are, by their nature, subject to risks and uncertainties, and any estimate and future proposals stated in the Presentation are based on certain assumptions and estimates and on management's judgements in light of currently available information only.

Shareholders and potential investors of the Company are advised not to place undue reliance on the information contained in the Presentation and should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, August 25, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu as executive directors; Dr. Ge Li, Mr. Yanling Cao and Ms. Jingwen Miao as non-executive directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive directors.

* *For identification purpose only*

WuXi Biologics
Global Solution Provider

Innovation, Execution & Global Scale Driving Sustained High Growth

2026 Interim Results

August 2026

Stock Code: 2269.HK

Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

We have provided adjusted net profit, adjusted net profit margin, adjusted gross profit, adjusted gross profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic earnings per share for the corresponding periods, which excludes the share-based compensation expenses, foreign exchange gains or losses, gains or losses from equity investments, asset divestiture and retirement, and related one-time costs, and are not required by, or presented in accordance with, IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

CONTENTS

01 2026 Interim Results



WuXi Biologics
Global Solution Provider

864 23% → **1,064**
Integrated Projects YoY

86 43% → **123**[1]
New Organic Projects Added

24 17% → **28**
Commercial Projects YoY

20.3 24% → **25.1**
Total Backlog (US$ Bn) (Jun 25 → Jun 26)

300 INDs &
20 BLAs/MAAs
Annual regulatory filing capacity in 2027E

14,705/5,180/ Key Talent Retention Rate 98.7%
Employees / Development Scientists

10.0 23.4% in USD / 18.4% → **11.8**
Revenue (RMB Bn) YoY

4.3 24.9% → **5.4**
Adj EBITDA (RMB Bn) YoY

2.4 38.4% → **3.3**
Adj Net Profit Attributable to Owners of the Company (RMB Bn) YoY

45.6% 280bps → **48.4%**
Adjusted Gross Profit Margin

45.6% / 28.0%
Adj EBITDA Margin / Margin of Adj Net Profit Attributable to Owners of the Company

0.59 37.3% → **0.81**
Adj Basic EPS (RMB)

Note:
1. Excludes 46 projects acquired from BioDlink

Robust New Project Momentum Supports Growth Visibility

The Company added 169 new integrated projects in H1 2026

- 123 organic and 46 acquired from BioDlink
- ~2/3 of the 123 new organic projects from the U.S. & EU
- 70%+ of the 169 new projects are bi- & multi-specifics and ADCs

Won 16 projects as of H1 2026, including 4 late-stage and 1 commercial

- 1 late-stage & 1 CMO wins are biosimilars
- More biosimilar opportunities currently under negotiation

78 late-stage & 28 CMO projects

- 1 additional BLA approval received in July 2026



Notes:
1. As of June 30, 2026
2. 28 Preclinical, 9 Phase I, 6 Phase II, 2 Phase III, and 1 commercial projects were from BioDlink (total 46)
3. The commercial manufacturing projects refer to the projects approved by regulatory authorities and signed CMO contracts with the Group

Strong Execution Fuels Surge in New Project Additions Since 2021

No. of Newly Added Integrated Projects by year



No. of "Win-the-Molecule" Projects (Organic) by year



Tech-transfer Excellence Underpins Win-the-Molecule Expansion

WuXi Biologics
Global Solution Provider

5+ Modalities



Proven Tech-transfer Execution

Consistent tech-transfer success across diverse biologics modalities reinforces client confidence & partnership continuity

Cell-Line Agnostic Process Expertise

Broad experience across industrial CHO platforms enables efficient process optimization & seamless tech transfer

WtM Drives CMO Expansion

- **"Win-the-Molecule"** has contributed **13 CMO** programs to date
- **WuXia™ TrueSite** (cell line 4.0) expected to become **a WtM differentiator** through **faster development timelines**, **higher productivity** & **improved client economics**

Note:
1. As of June 30, 2026

Broad-Based Revenue Growth Across Project Stages in H1 2026



- Pre-IND revenue rose **32%** YoY in USD in H1 2026, mainly driven by new IND-enabling projects signed in the past 12 months
- Early-phase revenue grew **15%** YoY in USD in H1 2026, primarily driven by projects progressing from preclinical to early clinical stages
- Late-stage + CMO revenue increased by **16%** YoY in USD, driven by clients' expanded clinical trial needs, partially offset by certain CMO order timing (prior year inventory building)

Diversified Geographic Growth in H1 2026, with China Regaining Strong Growth Momentum

58% of Revenue



17% of Revenue

17% of Revenue



8% of Revenue

- **North America**: Revenue grew 14% YoY, driven by new IND-enabling projects and Win-the-Molecule projects signed in the past 12 months
- **Europe:** Revenue was stable YoY, reflecting the Ireland vaccine business divestiture. Excluding that, EU would have grown 10% YoY
- **China:** Revenue rose 51% YoY, driven by renewed domestic demand amid an improving/stabilizing funding environment, and revenue contribution from the BioDlink acquisition
- **Rest of the World:** Revenue increased 43% YoY, reflecting the impact of strengthened BD efforts

Note:
1. The ROW market primarily includes Singapore, Japan, South Korea, Australia and Brazil

Solid Backlog Driven by Research Strength & Late-Phase/CMO Momentum



- As of June 30, 2026, total backlog reached US$25.1 bn, of which US$12.6 bn was service backlog
  - ❑ YoY growth was broader-based across late-stage development & commercial manufacturing, reflecting both pipeline progression & expanding client commitments on existing programs
- Upcoming potential milestone backlog reached US$12.4 bn, up $3.4 bn YoY, driven by newly signed bi- & multi-specific programs
- Backlog within 3 years was US$5.5 bn, up ~30% YoY, primarily driven by late-stage projects moving closer to commercialization, including several Phase III programs with PPQs scheduled over 2026–27, as well as incremental commercial orders from existing CMO programs

Notes:
1. Upcoming milestone revenue may take longer to receive at the various development stages as it depends on the success rate and progress of the projects
2. Results may not foot due to rounding

Complex Modalities Continue to Drive Pipeline Growth



One of the largest portfolios of complex biologics

71%
New signs bi- & multi-specifics + ADCs

399
First-in-Class programs

+ **221** bi- & multi-specifics covering different formats & **328** Antibody Drug Conjugates (ADC) projects

+ ADCs & bi-/multi-specifics have emerged as the industry's fastest-growing modalities, with pipeline CAGR of 26% and 20%, respectively (2023-2025)[3]

+ Technology leadership enables the Company to capture outsized growth from the industry's fastest-growing modalities, supporting a continued upgrade in revenue mix

Notes:
1. As of June 30, 2026, compared with projects number as of June 30, 2025
2. Bispecific Antibody (BsAb) included both WuXiBody™ projects and non-WuXiBody™ projects
3. Source: Evaluate Pharma, BCG analysis

Bi- & Multi-Specifics Sustain Strong Growth Momentum & Higher Retention

Bi- & Multi-Specifics Pipeline Momentum

- Nearly 20 bi- & multi-specifics currently in Research Services partnerships, eligible for potential milestones & royalties.
- One of the industry's largest & most advanced bi- & multi-specifics development portfolios
- 3 CMO programs, all high-potential assets.
- 3 PPQs scheduled in 2026E.
- H1 2026 revenue growth of ~30% YoY on strong prior year compare

Bi- & Multi-Specifics



"R"

"D"

"M"

Significantly Higher Complexity in Development & Manufacturing Improves Retention

- **Upstream:** Imbalanced expression creates chain-pairing & cell productivity challenges
- **Downstream:** Mispaired antibody species with similar size/charge make purification & impurity removal more difficult than mAbs.
- **Analytics/QC:** Structural complexity requires more advanced analytical characterization & QC testing.
- **Scalability:** Lower yields & tighter process control make scale-up & tech transfer more demanding. **WuXia™ TrueSite** helps **solve scalability & productivity challenges for complex molecules.**
- **Manufacturing troubleshooting:** More complex and technically demanding.

⇒ **Significantly higher technical barriers in development & manufacturing**

- ⇒ **Higher reliance on experienced CRDMO partners**
- ⇒ **Greater program retention vs. conventional mAbs**

Notes:
1. As of June 30, 2026
2. The commercial manufacturing projects refer to the projects approved by regulatory authorities and signed CMO contracts with the Group

H1 2026 Financials Review 02

H1 2026: Strong Revenue Growth with Remarkable Margin Expansion

Revenue RMB mm



IFRS Gross Profit RMB mm



Adjusted EBITDA (1) RMB mm



Adjusted Net Profit (2) RMB mm



Unadjusted Margin % Adjusted Margin %

Notes:

1. Adjusted EBITDA represents net profit before (i) interest expenses, income tax expenses, amortization and depreciation, (ii) share-based compensation, (iii) foreign exchange gains/losses and (iv) gains/losses from equity investments & asset divestiture and (v) transaction cost for acquisition of BioDlinK
2. Adjusted net profit excludes the share-based compensation expenses, foreign exchange gains/losses, gains/losses from equity investments & asset divestiture net of income tax, and transaction cost for acquisition of BioDlinK

H1 2026: Strong Earnings Growth Offset FX Headwind

IFRS Net Profit

RMB mm



IFRS Net Profit Attributable to Owners of the Company

RMB mm



Basic EPS (1)

RMB (Cents)



Adjusted Basic EPS (1)

RMB (Cents)



Note:

1. The authorized and issued shares of the Company were subdivided on the basis that every one (1) issued share is subdivided into three (3) subdivided shares (the "Share Subdivision"), which became effective on November 16, 2020. Basic and diluted earnings per share were stated after taking into account the effect of the Share Subdivision. Comparative figures have also been restated on the assumption that the Share Subdivision had been effective in the prior year

Gross Margin Expansion Supported by Continued Operating Leverage

Cost of Services as % of Revenue



Note:
1. Adjusted gross margin excludes the share-based compensation expenses

Strong Liquidity & Cash Generation Supporting Continued Expansion

AVAILABLE FUNDS	• Available funds approx. **RMB13.7 bn**[1] as of June 30, 2026 • Gearing Ratio **1.2%**, adequate cash on hand to sustain our growth globally
CAPEX	• H1 2026 CAPEX approx. **RMB2.8 bn,** primarily allocated to the expansion of WuXi Biologics & WuXi XDC facilities in Singapore, Biologics facility in the U.S., as well as XDC's expansion in China • 2026 CAPEX Plan: approx. **RMB7.1 bn** (including RMB1.5 bn deferred from 2025) • 2027 CAPEX Plan: approx. **RMB8 bn**
LOAN	• Approx. **RMB0.7 bn** borrowings as of June 30, 2026 • Available bank credit facilities of around **RMB7 bn**
CASH FLOW	• Free cash flow of **RMB1.5** bn in H1 2026 • Strong positive free cash flow expected in 2026

Note:
1. Including RMB0.7bn cash from Bestchrom, which has been reclassified into Assets Held for Sale upon the signing of the divestiture agreement.

03 Operation & Business Updates

50+ Active Research Services Partnerships with Embedded Milestone & Royalty Potential Across mAb, Multi-specifics & ADC

WuXi Biologics
Global Solution Provider



50%+ of programs are sponsored by ex-China clients

Multi-Layer Royalty Framework Enhancing Value Capture

WuXi Biologics
Global Solution Provider

Illustrative examples for royalty economics:
(US$ mm)

Drug A, net sales/year	**$1,000**	Drug A[1] = research services partnership, eligible for sales royalty		
***Sales* royalty @ 5% of net drug sales**	**$50**			
***Cell line* royalty @ 0.5% of net drug sales**				
	100% volume manufactured at WuXi Bio	**70% volume manufactured at WuXi Bio**	**100% manufactured externally**	**Traditional CMO @ 100% volume**
DS[2] mfg rev	**$50**	**$35**	**$0**	**$50**
***Sales* royalty**	**$50**	**$50**	**$50**	**$0**
***Cell line* royalty**	**$0**	**$1.5**	**$5**	**$0**
DS mfg OP @ 33% OPM	**$17**	**$12**	**$0**	**$17**
Royalty OP @ 100% OPM	**$50**	**$51.5**	**$55**	**$0**
Net Profit @ 20% income tax	**$53.2**	**$50.4**	**$44**	**$13.2**

Notes:
1- If Drug A uses WuXi Bio's proprietary cell line, commercial volume manufactured outside of WuXi Bio is subject to additional cell line royalty
2- DS assumed at 5% of net drug sales

- **Proprietary cell line platform enables additional royalty participation when commercial volume is manufactured externally**
  - **Creates asset-light, embedded participation in downstream product economics**

Established Track Record with Expanded IND Filing Capacity

WuXi Biologics
Global Solution Provider

Track Record

- Enabled a total of 854 IND filings as of June 2026
- As of June 2026, 68 INDs newly filed, while 77 IND clearance added
- In 2026, 180E INDs will be newly filed
- To expand capacity to 300 INDs and 20 BLAs/MAAs per year

Project Submission: Capacity Expansion





Numbers of INDs Filed (By Year)



100% of Clinical-Stage Client Assets Acquired by Large Pharma Remain with WuXi Bio for Commercial Launch, Driving Additional CMC Awards

WuXi Biologics
Global Solution Provider

99 client assets supported by WuXi Bio were licensed or acquired since 2018



Licensed / Acquired Assets

Additional Assets Awarded to WuXi Bio for CMC Work



41 additional assets were subsequently awarded to WuXi Bio for CMC



- ✓ **140 molecules associated with licensing/acquisitions have partnered with WuXi Bio**
- ✓ **60% of molecules licensed/acquired at Preclinical & Phase I clinical stage, highlighting attractive return on high-quality early-stage CMC investment**

Proven GMP Manufacturing Execution at Scale with High Quality

DS batches delivered since launch
2,600+

DS batch success rate (2022 – H1 2026)
98.7%

DP batches delivered since launch
2,670+

DP batch success rate (2022 – H1 2026)
99.6%

[1] As of June 30, 2026
[2] Data scope: Global MFG & Global MFG (US&APAC)

Scheduled PPQs Supporting Future CMO Growth

100% PPQ campaign success rate demonstrating strong execution & consistent quality

Cumulative PPQs



Annual PPQs



Biosimilar Opportunity: Technology & Regulatory Tailwinds Improve Sponsor Economics

WuXi Biologics
Global Solution Provider

WuXia™ TrueSite Technology Advantage

Faster Development, Higher Productivity & Lower COGS

- mAb titer avg 8+ g/L, up to 12 g/L
- 30-50% lower COGS & 30-40% lower manufacturing scale
- 1-3 months faster cell line development vs industry average

Growing Biosimilar Pipeline

17
Biosimilar projects as of June 2026

2
New signs in H1 2026

20
Committed over the next 3 years

10
Additional programs under active negotiation

Typically faster progression from Development to Manufacturing vs. innovative biologics

Evolving U.S. Regulatory Pathway

Potentially Faster, More Cost-Efficient Development Path

- FDA proposed reducing reliance on comparative efficacy studies => **shorten development timelines** & lower clinical development costs
- Greater reliance on analytical evidence plays to WuXi Bio's strengths in high-quality, accelerated CMC development

Four Key Pillars Underpinning Future Manufacturing Growth

WuXi Biologics
Global Solution Provider

FtM Pipeline

- **5+/5+/7+ additional commercial approvals** expected in **2027E/28E/29E**
- Continued ramp-up of existing CMO projects
- Expanded trial activities of late-stage projects

WtM Conversion

- **45** Phase III/CMO projects won since 2021
- **WuXia™ TrueSite** expected to become a **key WtM differentiator** through faster development, higher productivity & improved client economics

Biosimilar Opportunity

- WuXia™ TrueSite & evolving U.S. regulatory pathways expected to **accelerate biosimilar development**
- **Earlier commercial manufacturing opportunities through a shorter D-to-M cycle**
- 20 committed programs to bring significant manufacturing revenue

One DP Platform

- Integrated DP platform spanning development, manufacturing, drug devices, & clinical supplies, across formats from liquid/lyophilized vials & PFS to dual-chamber cartridge & autoinjectors
- Higher value capture per molecule through integrated DP offerings
- DP lines to **> 4x** over the next 3 yrs to meet client needs

Proven Global Regulatory Compliance & Quality Track Record

WuXi Biologics
Global Solution Provider

Regulatory Inspections and License Approvals

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

FDA

国家药品监督管理局
National Medical Products Administration

MHRA
Regulating Medicines and Medical Devices

Ministry of Food and Drug Safety

ANVISA

Pmda

HONG KONG

Health Canada

HSA
Health Sciences Authority

Australian Government
Department of Health
Therapeutic Goods Administration

HPRA

وزارة الصحة
MINISTRY OF HEALTH

NPRA
MALAYSIA

49 global regulatory inspections passed, including 23 EMA & FDA inspections

166 facility license approvals

15 facilities[1] certified for GMP manufacturing

2,000+ client quality audits passed, including **280+** qualified person audits

Notes:
1- Certified facilities exclude WuXi Vaccines Ireland site and Germany Leverkusen site.
2- All data as of June 30, 2026

Global End-to-End Network Enables Integrated R-D-M Delivery

WuXi Biologics
Global Solution Provider

500,000+ L
Bioreactor Capacity[1]

26 DS Facilities
- + **2,600+** batches since launch
- + **98.7%** success rate in the last 4.5 years

18 DP Facilities
- + **2,670+** batches since launch
- + **99.6%** success rate in the last 4.5 years



5 Research Centers
Shanghai WGQ, Shanghai FX, Chengdu in China; Boston in the U.S.; Singapore

10 Development Centers
Shanghai WGQ, Wuxi, Shanghai FX, Hangzhou, Suzhou, Chengdu in China; Cranbury NJ in the U.S.; Singapore, etc.

18 Manufacturing Centers
Wuxi, Hebei, Chengdu, Hangzhou in China; Wuppertal in Germany; Dundalk in Ireland; Worcester MA in the U.S.; Singapore, etc.

Notes:
1. The capacity figures are all planned capacity.
2. Singapore capacity has further expansion potential.

Expanding U.S. Investments to Build Integrated Local Capabilities

WuXi Biologics
Global Solution Provider

Seamless transfer of materials, samples, & products across sites

Drug Substance

MFG11: Worcester, MA (2029E)

- **Late-stage & commercial** manufacturing
- 6 x 6,000 L (36,000 L) capacity

5-hour drive

Process Development

Cranbury, NJ
(~ 89,000 ft²)

4-minute walk

Drug Substance

MFG18: Cranbury, NJ
(~ 66,000 ft²)

- **Clinical & commercial** (*new*) manufacturing
- 200 –2 x 2,000 L (**5,400 L**) bioreactor capacity
- Adding 2x2,000 L bioreactor capacity (**Total 13,300E L** bioreactor capacity)
- 1st PPQ project underway

20-minute drive

Drug Product

DP12: Robbinsville, NJ
(~ 90,000 ft²)

- Liquid vials
- Prefilled syringes (PFSs)

On-Site Clinical Supply
Fast distribution to clinical testing centers

Singapore Build-Out Advances an End-to-End Biologics Hub



- WuXi Biologics' modular Drug Product (DP) facility structurally topped out; on track for operations in 2027
  - 3 pre-filled syringe (PFS) lines, 2 vial lines for liquid & lyophilized products
  - ~100 million units annual capacity
- WuXi Biologics' modular Drug Substance (DS) facility progressing on schedule

- WuXi XDC mAb/bioconjugate suite achieved GMP release
- WuXi XDC DP facility on track for GMP release by August 2026, with designed capacity of 8m vials/year

Expanding Manufacturing Capacity in China in Response to Strong Customer Demand

WuXi Biologics
Global Solution Provider

Microbial manufacturing site in Chengdu

- GMP release targeted by YE2026
- **15,000L** microbial DS capacity, expandable to **60,000L**
- China's first dual-chamber lyophilization production line and a vial-filling line; >10 million vials DP capacity
- Powered by proprietary **EffiX™** *E. coli* expression platform

MFG17 in Fengxian, Shanghai

- Completed **1st GMP production campaign with zero deviations**
- **9,000L** capacity, expandable to **20,000L**
  - Flexible batch sizes
- Supports both **clinical & commercial** manufacturing
- **Continuous** manufacturing line expected by **2027**

Transcenta

- Recently announced proposed acquisition of **Transcenta's manufacturing facility**
- **Integrated process development, DS, & DP** capabilities adjacent to WuXi Bio's MVP site => **operational synergies & flexible capacity expansion**
- Attractive return profile with a short payback period, underpinned by strong & growing client demand

Following stronger-than-expected customer demand, accelerating manufacturing capacity expansion through brownfield investments & strategic asset acquisitions

Digital Platforms Drive Speed, Quality & Operational Efficiency

WuXi Biologics
Global Solution Provider

Win and Serve Our Clients

One-Stop Client Portal

+ Best-in-class digital client experience with industry-leading, secure, cloud-based platform that enables clients to seamlessly generate proposals, access experimental data and reports, obtain cost estimates, and track shipment



Lab Core Operating Systems & Analytics to Accelerate Discovery & Development

BioFoundry

+ Digital twin representation of our physical lab processes, connected to lab devices & equipment enabling no-code workflow configuration

400+
Workflows

In silico

+ In silico modeling and analytics to reduce wet-lab experimentation and improve process development

30+
Applications

Manufacturing & Quality Control

EBR

+ Electronic Batch Record (EBR) rollout to improve quality, productivity, speed, and flexibility

~40%
Productivity Increase

Advanced Planning

+ Data & advanced analytics enable planning & scheduling to optimize labor, material, & equipment allocation to improve utilization under complex scenarios

~20%
Efficiency Improvement

PatroLab™:
A Platform Solution For Bioprocess Digital Twin Implementation at WuXi Biologics

WuXi Biologics
Global Solution Provider

Raman Data Acquisition and Repository

Raman Spectroscopy





Real-time monitoring of 40+ in-process targets and PQAs

Process Knowledge Hub

Multi-Source Data Integration

+ Inline process data: OSI PI system
+ Offline analytics: Manufacturing Data Hub
+ Raman spectroscopy

Modeling Management Center

Feature Engineering

Multivariate analysis



Raman model

Digital Learning

Mechanistic model

+ Brx pCO2 model
+ Frontal curve model
+ Column loading by UV
+ DSP in-process modeling

In silico process modeling & simulation

Process Orchestration Interface

Model Visualization



Manufacturing management Enhancement

+ Real-time performance simulation
+ Instantaneous OOT alarm
+ Root cause identification

Interactive user interface for model visualization & control

BestChrom Divestiture: Portfolio Optimization to Enhance Strategic Focus

BestChrom

51.1% owned subsidiary focused on biologics purification media & chromatography columns

WuXi Bio first invested in BestChrom in 2019 to strengthen supply security and has supported its growth since. With the original strategic objective largely achieved, the proposed divestiture represents a natural evolution toward portfolio optimization & more focused capital allocation

Strategic Rationale

Sharpen strategic focus on core CRDMO businesses

Transaction Timeline

Signed July 2026 -> Expected closing December 2026

Advanced Technology Platforms – Cornerstone of Future Success

04

Expanding Proprietary ADC Technologies Across Conjugation, Linkers & Payloads

Broadening proprietary ADC technology platforms with increasing project adoption & clinical validation

WuXiDARx™

Flexible DAR control without antibody engineering or enzymes

- ✓ **WuXiDAR4™:** Applied to **10+** iCMC projects, **8** in clinical development
- ✓ **WuXiDAR2™ :** Highly homogeneous ADC and APC achieved; First client ADC (DAR2) project advanced to iCMC-ready stage
- ✓ **WuXiDAR1™ :** Highly homogeneous AOC(DAR1) achieved
- ✓ **WuXiDARx™ dpADC:**
  - Successfully applied to **10+** dpADCs;
  - First project advanced to **iCMC development**

WuXi Payload-Linker™

Offering a variety of PLs with favorable hydrophilicity for next-gen ADCs

- ✓ **WuXiTecan-2™ : Successfully out-licensed** the technology to **2** companies (**3** iCMC projects)
- ✓ **WuXiLinker™ :** Proprietary hydrophilic linker applied to other payloads, creating favorable PLs
  - **WuXiMMAE™**
  - **WuXiATRi™**
  - **WuXiEribulin™**
- ✓ **Novel Payloads**
  - **DDRi:** WuXiTecan-2 synergizer
  - **Immune agonist:** WuXiTecan-2 synergizer
- ✓ **X-LinC™ :** Novel stable connector

Next-Gen Targeted Integration Platform Accelerates Cell Line Development

WuXi Biologics
Global Solution Provider

WuXia™ Platform Technology Innovation

Random Integration

2010

WuXia™ 2.0

Semi-Targeted Integration

2019

WuXia™ 3.0 WuXia RidGS

Targeted Integration

2025

WuXia™ TrueSite

Clone Diversity

Clone Stability

Historical

3,000+ cells screened to produce 2 g/L (mAb) in ~6 months

Current

< 30 cells screened to achieve 8+ g/L (mAb) in ~2.5 months

IND Dossier ready in ~6 months

WuXia™ TrueSite Improves Client Economics While Expanding WuXi Bio Value Capture

- **Accelerated development timelines support higher-margin development offerings**
- **Higher titer & productivity reduce COGS significantly, a win-win for WuXi Bio and clients**
  - Expected to become a **key driver of Win-the-Molecule** strategy
  - Particularly attractive for **biosimilar** programs, where development speed & lower COGS are critical
- **Cell line royalties apply when commercial manufacturing conducted externally**

Acceleration

1-3 months faster vs industry avg cell line development

Productivity

mAb avg 8+ g/L, up to 12 g/L; bsAb avg 7.5+ g/L, up to 10 g/L

> 2x industry avg titer, **30-50% lower** COGS

30-40% lower manufacturing scale

Rapid Adoption Across Multiple Modalities



- As of June 30, 2026, WuXia™ TrueSite has been applied in **70+** projects since launch (Oct 2025) across mAbs, bi- & multi-specifics and other formats
- 1st IND approval expected in **Sep 2026**

05 WBS (WuXi Bio Business System) and ESG as Key Components of Business Strategy



WuXi Bio Business System H1 2026 Highlights



Premier Quality

Enhance reporting standards
Mitigate quality risk

Revenue

Enhance customer retention
Expand into new business

Labor Efficiency

Deploy digital initiatives
Implement standard work

Material Cost Saving

Optimize material usage
Improve inventory management

Cost Saving

Enhance facility utilization
Improve maintenance/logistics management

ESG Optimization

Reduce energy, water, waste and CO_2 emissions

Trustworthy Partner with a Strong Sustainability Commitment

WuXi Biologics
Global Solution Provider

Align with United Nations Sustainable Development Goals

SUSTAINABLE DEVELOPMENT GOALS

WE SUPPORT UN GLOBAL COMPACT

ESG+20 引领全球企业变革20年

SCIENCE BASED TARGETS
DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

Join International Sustainable Development Initiatives

PSCI PHARMACEUTICAL SUPPLY CHAIN INITIATIVE
Building responsible supply chains

UN WOMEN WOMEN'S EMPOWERMENT PRINCIPLES

ISO

Industry Leader with Outstanding ESG Performance

Top 1%
Corporate Sustainability Assessment (CSA) 2025 Score

S&P Dow Jones Best-in-Class Indices
S&P Global ESG Indices
(2023-2026)

MSCI ESG RATINGS AAA
MSCI Selection Indexes Constituents 2026

MSCI ESG Ratings AAA
MSCI Selection Indexes
(2023-2026)

CDP A List 2025 – Climate Change
CDP A List 2025 – Water Security
CDP 2025 – Supplier Engagement

A List – Climate Change
A List – Water Security
A List - Supplier Engagement
(2023-2025)

FTSE4Good

FTSE4Good Emerging Index
Industry Top 4%
(2021-2026)

Trusted Partner to Enable Global Clients

PLATINUM Top 1% ecovadis Sustainability Rating JAN 2026

EcoVadis Platinum Medal
Global 1%
(2023-2026)

Sustainalytics Industry ESG Leader 2026
Sustainalytics Regional ESG Leader 2026

Sustainalytics Negligible-Risk
Industry & Regional ESG Leader
(2021-2026)

Corporate ESG Performance Prime
RATED BY ISS ESG

Prime Award
ISS ESG Corporate Rating
(2023-2025)

恒生指數 HANG SENG INDEXES

ESG 50 Index
Hang Seng Corporate
Sustainability Benchmark Index
(2023-2025)

* Data as of June 30, 2026

Summary & Outlook 06

Three High-Growth Modalities Powering WuXi Bio's Accelerated Growth

WuXi Biologics
Global Solution Provider

Bi- & Multi-Specifics

- **221 bi- & multi-specifics** in pipeline, **high growth modality** at WuXi Bio
  - 3 currently in CMO (all high-potential assets)
- **Proprietary CD3 TCE platform**
  - E.g. CD3xCD19, CD3xCD20, CD3xPSMA, CD3xCD19xCD20
- **bsAbs targeting clinically validated and/or emerging pathways**
  - E.g. PD-(L)1xVEGF, DLL4xVEGF, EGFR×TGF-β, 4-1BBxCLDN18.2

ADCs

- **328 ADCs** in pipeline, **high growth modality** at WuXi Bio
  - **POC-validated MoAs with differentiated molecular structure and/or indication focus** e.g. HER2, TROP2, FRα, Nectin-4
  - **Emerging MoAs** e.g. B7-H3, DLL3, ROR1, CLDN6, CLDN18.2, GPRC5D
  - **Novel conjugates** e.g. drug-Fc conjugate

mAbs & Other Proteins

- **487 mAbs and other proteins** in pipeline, with **multiple $billion-dollar franchises** in late-stage/CMO
  - E.g. FcRn, IGF1R, CD19-mediated B-cell silencer, selective inhibitor of active C1s, IL23,IL-17, α4β7 integrin, TL1A, TTR amyloid depleter, mAbs for autoimmune, kidney, and allergic diseases

Technology Leadership & Execution Excellence Position WuXi Bio for Accelerating Growth

H1 2026 Summary

- Revenue +23.4% YoY in USD with GPM +350bps YoY, reflecting continued operating leverage
  - Bi-/multi-specifics revenue + ~30% YoY on strong prior year compare, continuing to upgrade business mix
- R: Growth on track
- D: Record project additions & expanding IND filing capacity support future growth visibility
  - 169[1] new integrated projects (123 organic, +43% YoY) & 68 IND filings
  - Annual IND filing capacity expanding to 300 in 2027
- M: CMO momentum continued to strengthen
  - Hebei site received its 1st BLA approval in July following FDA inspection
  - Year-to-date, Ireland site has secured 3 large-scale manufacturing projects & commenced tech-transfer
- Ongoing global footprint expansion & digital transformation
  - Accelerating manufacturing capacity expansion in China through brownfield investments & potential strategic asset acquisitions

Outlook

FY2026: raising revenue growth to 20 – 23% YoY in constant currency (vs prior 16-20% YoY); 15 – 18% YoY reported (vs prior 13 – 17% YoY)

- Profitable growth
- Strong demand with pipeline mix continuing to upgrade towards complex modalities
- Technology differentiation becoming increasingly commercial
  - WuXia™ TrueSite 70+ within months of launch, expected to strengthen both FtM/WtM competitiveness & particularly attractive for biosimilars
- Visibility in manufacturing growth supported by our 4 distinct pillars
- CapEx expansion & portfolio actions remain demand-driven & disciplined

Well-positioned to capture incremental demand from digital advances in drug discovery & next-gen therapeutic platforms

See 20% Revenue CAGR over the Next 3 Years

- M CAGR of 30%
- Additional MFG projects each generating US$100m+/year

Note:
1. Including 46 projects acquired from BioDlink

WuXi Biologics
Global Solution Provider

WuXi Biologics

Every Biologic Can Be Made

- Premier Quality
- Innovative Technologies
- Perfect Execution
- Fast Speed
- Competitive Cost